LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will host an in-person and virtual Research & Development event (“The Road Taken”) on Saturday, November 12, 2022, from 2:00 p.m. to 5:00 p.m. ET at the Prudential Tower in Boston, MA.
The Road Taken will feature both key opinion leaders at the forefront of immunotherapy development for cancer and Agenus’ expanding leadership team. During the event, speakers will highlight recent developments within the Agenus clinical-stage pipeline of novel immunotherapy programs, study details involving botensilimab, a multi-functional Fc-enhanced anti-CTLA-4 which activates innate and adaptive immune responses, opportunities to combine Agenus pipeline assets to overcome immuno-oncology resistance and strategies to reach commercialization as rapidly as possible.
Featured speakers will include:
- Michael Atkins, MD, Deputy Director & Professor, Acting Chief, Division of Hematology/Oncology MedStar Georgetown University Hospital; SITC 2022 Lifetime Achievement Award Recipient
- Breelyn Wilky, MD, Director of Sarcoma Medical Oncology, Deputy Associate Director for Clinical Research University of Colorado Medicine; Principal Investigator/Presenter C-800 Study
- Steven O’Day, MD, Chief Medical Officer, Agenus
- Joseph Grossman, MD, VP and Head of Exploratory Medicines, Agenus
- Patricia Carlos, Chief Regulatory, Quality, and Safety Officer, Agenus
The scientific program will take place from 2:00 p.m. to 4:00 p.m. ET and will be followed by a reception from 4:00 p.m. to 5:00 p.m. ET.
The event will be webcast live and institutional investors and research analysts are invited to attend in person. Individuals interested in attending the event in person should contact Agenus Investor Relations at investorrelations@agenus.com. The webcast will be available on the Investors section of the Agenus website at investor.agenusbio.com. To register for the webcast, please click here. Following the webcast, an archived version will be available on the Agenus website.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its subsidiary MiNK Therapeutics), and adjuvants (through its subsidiary SaponiQx). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements relating to our technologies, therapeutic candidates, and capabilities, for instance, statements regarding therapeutic benefit and efficacy, mechanism of action, potency, durability, and safety and tolerability profile of our therapeutic candidates, both alone and in combination with each other and/or other agents; statements regarding future plans, including research, clinical, regulatory, and commercialization plans; and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission and available on our website: www.agenusbio.com. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contact
Ethan Lovell
Chief External Affairs & Communications Officer
339-927-1763
ethan.lovell@agenusbio.com
